Unknown

Dataset Information

Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study.


ABSTRACT:

Background

People with severe mental illness are two to three times more likely to be overweight or have obesity than the general population and this is associated with significant morbidity and premature mortality. Liraglutide 3 mg is a once daily injectable GLP-1 receptor agonist that is licensed for the treatment of obesity in the general population and has the potential to be used in people with severe mental illness.

Aims

To record the expectations and experiences of people with schizophrenia, schizoaffective disorders or first episode psychosis taking daily liraglutide 3 mg injections in a clinical trial for the treatment of obesity. To seek the views of healthcare professionals about the feasibility of delivering the intervention in routine care.

Methods

Qualit

SUBMITTER: Barnard-Kelly K 

PROVIDER: S-EPMC8740474 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature